Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE RANKIN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1922027853
CMS profile
132925
Location
DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$6,373.98

97 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $3,980.38 13
Food and Beverage $2,387.60 83
Education $6.00 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE RANKIN

NPI 1922027853 · CMS profile ID 132925

Allopathic & Osteopathic Physicians / Family Medicine

DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922027853?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922027853?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922027853?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1922027853?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

97 matching records · $6,373.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 97 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 97.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $14.0012/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673828509 CMS
Ultragenyx Pharmaceutical Inc. $16.1512/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703130877 CMS
GlaxoSmithKline, LLC. $11.6512/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671435733 CMS
AstraZeneca Pharmaceuticals LP $12.0811/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685611263 CMS
AstraZeneca Pharmaceuticals LP $13.7511/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685974777 CMS
Novo Nordisk Inc $19.7011/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674649529 CMS
Astellas Pharma US Inc $19.4811/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655737003 CMS
AstraZeneca Pharmaceuticals LP $12.6911/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685469465 CMS
Allergan Inc. $19.3011/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670990317 CMS
Allergan Inc. $17.9211/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701305917 CMS
AstraZeneca Pharmaceuticals LP $13.6410/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685090245 CMS
PFIZER INC. $13.1510/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673176687 CMS
GlaxoSmithKline, LLC. $11.4710/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671488733 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.0610/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700170735 CMS
Lilly USA, LLC $15.4910/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657713505 CMS
Teva Pharmaceuticals USA, Inc. $11.8110/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697773845 CMS
AstraZeneca Pharmaceuticals LP $13.5910/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685325041 CMS
Lilly USA, LLC $11.9410/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657727481 CMS
Lilly USA, LLC $14.9009/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657713503 CMS
AstraZeneca Pharmaceuticals LP $12.2009/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685537981 CMS
SANOFI-AVENTIS U.S. LLC $20.2809/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694130609 CMS
Amgen Inc. $13.0209/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662228141 CMS
Teva Pharmaceuticals USA, Inc. $18.2409/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697731571 CMS
PFIZER INC. $12.3708/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672526481 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.2008/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700170737 CMS
AstraZeneca Pharmaceuticals LP $16.5708/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685251551 CMS
AstraZeneca Pharmaceuticals LP $15.9207/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685288547 CMS
Allergan Inc. $13.9107/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670990309 CMS
AstraZeneca Pharmaceuticals LP $12.5207/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685857727 CMS
Amgen Inc. $16.0507/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662228139 CMS
PFIZER INC. $596.0107/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672596863 CMS
Merck Sharp & Dohme Corporation $5.7607/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695633539 CMS
GlaxoSmithKline, LLC. $13.9107/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671380680 CMS
Merck Sharp & Dohme Corporation $12.2107/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695618271 CMS
AstraZeneca Pharmaceuticals LP $19.1206/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685280647 CMS
AstraZeneca Pharmaceuticals LP $12.6906/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685200601 CMS
PFIZER INC. $15.9806/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672148949 CMS
Novo Nordisk Inc $23.5806/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674432943 CMS
Merck Sharp & Dohme Corporation $9.4906/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695556737 CMS
Teva Pharmaceuticals USA, Inc. $12.7106/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697713715 CMS
Novo Nordisk Inc $16.2406/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674432945 CMS
PFIZER INC. $15.2006/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672229199 CMS
PFIZER INC. $204.8606/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672260617 CMS
PFIZER INC. $271.1306/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672260619 CMS
Astellas Pharma US Inc $17.1206/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655737001 CMS
PFIZER INC. $14.9106/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672198613 CMS
Merck Sharp & Dohme Corporation $29.7705/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804329 CMS
Merck Sharp & Dohme Corporation $49.9805/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804331 CMS
Merck Sharp & Dohme Corporation $50.0005/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804333 CMS
Merck Sharp & Dohme Corporation $78.4105/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804335 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,373.98 97
PY2020 $739.07 44
PY2021 $406.88 25
PY2022 $30.36 2
PY2023 $3,057.34 11
PY2024 $1,612.22 12
PY2025 $249.99 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,755.45 1
PY2025 Principal investigator $4,230,288.19 209
PY2024 Recipient $1,330.16 13
PY2024 Principal investigator $3,187,354.20 327
PY2023 Recipient $893.27 4
PY2023 Principal investigator $6,323,793.75 2,767
PY2022 Recipient $462.00 2
PY2022 Principal investigator $6,941,300.42 589
PY2021 Recipient $15.00 1
PY2021 Principal investigator $10,036,876.19 348
PY2020 Recipient $10,602.17 4
PY2020 Principal investigator $3,545,507.10 644
PY2019 Principal investigator $2,410,610.06 875

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

349 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $15,213.07 12/31/2021 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 848739029
Principal investigator 1 Janssen Research & Development, LLC $500.00 12/29/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in No dispute reported 06/30/2026 787819167
Principal investigator 1 PFIZER INC. $63,863.88 12/29/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832538155
Principal investigator 1 Janssen Pharmaceuticals, Inc $22,656.00 12/28/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787575823
Principal investigator 1 Janssen Research & Development, LLC $19,602.00 12/28/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787819333
Principal investigator 1 Janssen Research & Development, LLC $2,369.00 12/28/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819559
Principal investigator 1 PFIZER INC. $66,862.91 12/28/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832538165
Principal investigator 1 ModernaTX, Inc. $1,514.00 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945079
Principal investigator 1 ModernaTX, Inc. $1,816.80 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945085
Principal investigator 1 ModernaTX, Inc. $3,028.00 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945091
Principal investigator 1 ModernaTX, Inc. $3,028.00 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945093
Principal investigator 1 ModernaTX, Inc. $4,844.80 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945099
Principal investigator 1 ModernaTX, Inc. $7,267.20 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945103
Principal investigator 1 ModernaTX, Inc. $8,301.40 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945109
Principal investigator 1 ModernaTX, Inc. $20,059.63 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945137
Principal investigator 1 ModernaTX, Inc. $30,089.45 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945147
Principal investigator 1 ModernaTX, Inc. $31,927.50 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945149
Principal investigator 1 ModernaTX, Inc. $33,161.88 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945153
Principal investigator 1 ModernaTX, Inc. $33,189.75 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945155
Principal investigator 1 ModernaTX, Inc. $59,231.25 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945167
Principal investigator 1 ModernaTX, Inc. $62,293.05 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945169
Principal investigator 1 ModernaTX, Inc. $217,911.86 12/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945187
Principal investigator 1 PFIZER INC. $722,086.16 12/24/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832537751
Principal investigator 1 PFIZER INC. $951.60 12/23/2021 Non-covered Recipient Entity
University Clinical ResearchDeLand LLC
A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE No dispute reported 06/30/2026 832538175
Principal investigator 1 Janssen Research & Development, LLC $18,900.00 12/22/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819607
Principal investigator 1 Janssen Research & Development, LLC $46,600.00 12/22/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819625
Principal investigator 1 ModernaTX, Inc. $700.00 12/22/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945063
Principal investigator 1 ModernaTX, Inc. $875.95 12/22/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945071
Principal investigator 1 ModernaTX, Inc. $2,785.59 12/22/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945089
Principal investigator 1 ModernaTX, Inc. $8,023.85 12/22/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945107
Principal investigator 1 ModernaTX, Inc. $14,107.50 12/22/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945127
Principal investigator 1 ModernaTX, Inc. $29,149.94 12/22/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945145
Principal investigator 1 Janssen Research & Development, LLC $50.00 12/17/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819383
Principal investigator 1 Janssen Research & Development, LLC $200.00 12/17/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819401
Principal investigator 1 Janssen Research & Development, LLC $900.00 12/17/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819471
Principal investigator 1 Janssen Research & Development, LLC $6,400.00 12/17/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819575
Principal investigator 1 ModernaTX, Inc. $34,303.50 12/17/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945157
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,998.46 12/16/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 851031567
Principal investigator 1 ModernaTX, Inc. $1,514.00 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945075
Principal investigator 1 ModernaTX, Inc. $1,514.00 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945077
Principal investigator 1 ModernaTX, Inc. $3,330.80 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945095
Principal investigator 1 ModernaTX, Inc. $4,844.80 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945097
Principal investigator 1 ModernaTX, Inc. $8,478.40 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945111
Principal investigator 1 ModernaTX, Inc. $13,323.19 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945121
Principal investigator 1 ModernaTX, Inc. $18,053.67 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945131
Principal investigator 1 ModernaTX, Inc. $36,371.09 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945159
Principal investigator 1 ModernaTX, Inc. $48,138.21 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945161
Principal investigator 1 ModernaTX, Inc. $82,058.75 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945175
Principal investigator 1 ModernaTX, Inc. $93,565.15 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945177
Principal investigator 1 ModernaTX, Inc. $101,740.74 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945179
Principal investigator 1 ModernaTX, Inc. $192,552.84 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945185
Principal investigator 1 ModernaTX, Inc. $724,152.64 12/15/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945189
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $202.50 12/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 851031171
Principal investigator 1 GRT US Holding, Inc. $6,450.00 12/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AV001 No dispute reported 06/30/2026 839391349
Principal investigator 1 GRT US Holding, Inc. $1,500.00 12/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AV001 No dispute reported 06/30/2026 839391351
Principal investigator 1 PFIZER INC. $695.93 12/07/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832536425
Principal investigator 1 Astellas Pharma Inc $1,428.79 12/02/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function No dispute reported 06/30/2026 813552937
Principal investigator 1 Astellas Pharma Inc $144.84 12/02/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function No dispute reported 06/30/2026 813552943
Principal investigator 1 Astellas Pharma Inc $2,996.31 12/02/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function No dispute reported 06/30/2026 813552949
Principal investigator 1 Astellas Pharma Inc $296.39 12/02/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function No dispute reported 06/30/2026 813552955
Principal investigator 1 Eli Lilly and Company $195.16 11/30/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 819468549
Principal investigator 1 Janssen Pharmaceuticals, Inc $51,507.00 11/22/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787575835
Principal investigator 1 Janssen Research & Development, LLC $10,228.00 11/19/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819591
Principal investigator 1 ModernaTX, Inc. $875.95 11/19/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945069
Principal investigator 1 ModernaTX, Inc. $13,545.77 11/19/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945123
Principal investigator 1 ModernaTX, Inc. $56,201.72 11/19/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945165
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $476.40 11/18/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 851030051
Principal investigator 1 PFIZER INC. $2,531.93 11/18/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832713223
Principal investigator 1 Janssen Research & Development, LLC $13,300.00 11/17/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787819312
Principal investigator 1 ModernaTX, Inc. $500.00 11/17/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945061
Principal investigator 1 SEIKAGAKU CORPORATION $3,614.00 11/12/2021 Non-covered Recipient Entity
University Clinical Res-Deland, LLC (WIRE)
6603/1133 No dispute reported 06/30/2026 807679507
Principal investigator 1 ABBVIE INC. $150.00 11/10/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects with Moderately to Severely Active Ulcerative Colitis or Crohns Disease No dispute reported 06/30/2026 792482527
Principal investigator 1 ModernaTX, Inc. $13,930.52 11/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945125
Principal investigator 1 ModernaTX, Inc. $63,058.50 11/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945171
Principal investigator 1 PFIZER INC. $2,540.04 11/10/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832744479
Principal investigator 1 SEIKAGAKU CORPORATION $2,710.50 11/05/2021 Non-covered Recipient Entity
University Clinical Res-Deland, LLC (WIRE)
6603/1133 No dispute reported 06/30/2026 807679505
Principal investigator 1 Janssen Pharmaceuticals, Inc $50.00 11/03/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787575813
Principal investigator 1 ModernaTX, Inc. $141.08 11/03/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945057
Principal investigator 1 PFIZER INC. $75.00 11/03/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832830839
Principal investigator 1 PFIZER INC. $8,891.80 10/30/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832877883
Principal investigator 1 ModernaTX, Inc. $705.38 10/29/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945065
Principal investigator 1 ModernaTX, Inc. $2,116.13 10/29/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945087
Principal investigator 1 ModernaTX, Inc. $12,404.34 10/29/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945119
Principal investigator 1 ModernaTX, Inc. $167,105.90 10/29/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945183
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,640.53 10/28/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 851029429
Principal investigator 1 ModernaTX, Inc. $500.00 10/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945059
Principal investigator 1 ModernaTX, Inc. $72,765.00 10/27/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945173
Principal investigator 1 PFIZER INC. $11,379.86 10/27/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832721739
Principal investigator 1 Janssen Research & Development, LLC $6,778.00 10/22/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819659
Principal investigator 1 PFIZER INC. $73.75 10/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 832630179
Principal investigator 1 PFIZER INC. $486.25 10/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 832632445
Principal investigator 1 PFIZER INC. $15.00 10/21/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832906061
Principal investigator 1 Janssen Pharmaceuticals, Inc $60,738.00 10/20/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787575845
Principal investigator 1 Janssen Research & Development, LLC $4,608.00 10/20/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787819351
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,500.00 10/19/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
C3718-301 No dispute reported 06/30/2026 831594747
Principal investigator 1 PFIZER INC. $16,443.72 10/16/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832803589
Principal investigator 1 ModernaTX, Inc. $1,633.50 10/13/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945081
Principal investigator 1 ModernaTX, Inc. $142,446.60 10/13/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945181
Principal investigator 1 SEIKAGAKU CORPORATION $1,175.00 10/13/2021 Non-covered Recipient Entity
University Clinical Res-Deland, LLC (WIRE)
6603/1133 No dispute reported 06/30/2026 807679501
Principal investigator 1 SEIKAGAKU CORPORATION $770.00 10/13/2021 Non-covered Recipient Entity
University Clinical Res-Deland, LLC (WIRE)
6603/1133 No dispute reported 06/30/2026 807679503
Principal investigator 1 PFIZER INC. $20,981.14 10/09/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832891913
Principal investigator 1 PFIZER INC. $1,537.50 10/08/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832882115
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,302.85 10/07/2021 Non-covered Recipient Entity
ACCEL CLINICAL
A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS No dispute reported 06/30/2026 827899257
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,302.85 10/07/2021 Non-covered Recipient Entity
ACCEL CLINICAL
A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS No dispute reported 06/30/2026 827899259
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 10/06/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819641
Principal investigator 1 PFIZER INC. $43,850.26 10/05/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832797475
Principal investigator 1 Janssen Research & Development, LLC $150.00 10/01/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787819294
Principal investigator 1 Janssen Research & Development, LLC $25.00 10/01/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819369
Principal investigator 1 Janssen Research & Development, LLC $300.00 10/01/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819421
Principal investigator 1 Janssen Research & Development, LLC $330.00 10/01/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819437
Principal investigator 1 Janssen Research & Development, LLC $435.00 10/01/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819453
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 10/01/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819491
Principal investigator 1 Janssen Research & Development, LLC $1,312.00 10/01/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819507
Principal investigator 1 Janssen Research & Development, LLC $1,328.00 10/01/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819521
Principal investigator 1 Janssen Research & Development, LLC $1,768.00 10/01/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819541
Principal investigator 1 ModernaTX, Inc. $846.45 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945067
Principal investigator 1 ModernaTX, Inc. $1,141.43 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945073
Principal investigator 1 ModernaTX, Inc. $1,751.90 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945083
Principal investigator 1 ModernaTX, Inc. $7,053.75 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945101
Principal investigator 1 ModernaTX, Inc. $7,476.98 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945105
Principal investigator 1 ModernaTX, Inc. $10,722.98 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945113
Principal investigator 1 ModernaTX, Inc. $11,997.79 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945115
Principal investigator 1 ModernaTX, Inc. $12,217.10 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945117
Principal investigator 1 ModernaTX, Inc. $16,469.87 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945129
Principal investigator 1 ModernaTX, Inc. $18,832.23 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945133
Principal investigator 1 ModernaTX, Inc. $18,832.23 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945135
Principal investigator 1 ModernaTX, Inc. $20,599.52 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945139
Principal investigator 1 ModernaTX, Inc. $23,102.96 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945141
Principal investigator 1 ModernaTX, Inc. $24,690.69 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945143
Principal investigator 1 ModernaTX, Inc. $32,993.60 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945151
Principal investigator 1 ModernaTX, Inc. $52,697.93 10/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860945163
Principal investigator 1 PFIZER INC. $90.00 09/30/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832837299
Principal investigator 1 Moderna TX, Inc. $141.08 09/29/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342967
Principal investigator 1 Moderna TX, Inc. $542.70 09/29/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342983
Principal investigator 1 PFIZER INC. $8,916.94 09/29/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 832908283
Principal investigator 1 PFIZER INC. $41,737.49 09/25/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832694825
Recipient Eli Lilly and Company $15.00 09/24/2021 Covered Recipient Physician A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819443119
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,283.20 09/24/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787575803
Principal investigator 1 Janssen Research & Development, LLC $13,784.00 09/24/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819061
Principal investigator 1 Janssen Research & Development, LLC $500.00 09/24/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787819257
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,422.31 09/23/2021 Non-covered Recipient Entity
ACCEL CLINICAL
A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS No dispute reported 06/30/2026 827899103
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,422.31 09/23/2021 Non-covered Recipient Entity
ACCEL CLINICAL
A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS No dispute reported 06/30/2026 827899117
Principal investigator 1 Janssen Pharmaceuticals, Inc $40,084.00 09/22/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787575762
Principal investigator 1 Janssen Research & Development, LLC $28,736.00 09/22/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819079
Principal investigator 1 Janssen Research & Development, LLC $4,822.00 09/22/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787819235
Principal investigator 1 PFIZER INC. $464.00 09/22/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832744469
Principal investigator 1 PFIZER INC. $9,945.00 09/22/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832902909
Principal investigator 1 PFIZER INC. $20,463.36 09/21/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832848203
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,995.00 09/17/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787575793
Principal investigator 1 PFIZER INC. $21,839.00 09/14/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832835035
Principal investigator 1 Moderna TX, Inc. $6,021.34 09/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342915
Principal investigator 1 Moderna TX, Inc. $5,600.00 09/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342919
Principal investigator 1 Moderna TX, Inc. $350.00 09/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342953
Principal investigator 1 Moderna TX, Inc. $500.00 09/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342997
Principal investigator 1 Moderna TX, Inc. $1,551.83 09/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343013
Principal investigator 1 Moderna TX, Inc. $1,269.68 09/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343041
Principal investigator 1 Moderna TX, Inc. $28,215.00 09/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343103
Principal investigator 1 Moderna TX, Inc. $68,453.10 09/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343133
Principal investigator 1 Moderna TX, Inc. $515.57 09/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343159
Principal investigator 1 PFIZER INC. $30.00 09/09/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832830691
Principal investigator 1 Janssen Pharmaceuticals, Inc $7,000.00 09/08/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787575781
Principal investigator 1 PFIZER INC. $33,407.89 09/08/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832732819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $75.00 09/07/2021 Non-covered Recipient Entity
Accel Research Sites - DeLand Clinical Research Unit
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828418705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/07/2021 Non-covered Recipient Entity
Accel Research Sites - DeLand Clinical Research Unit
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828418707
Principal investigator 1 Alnylam Pharmaceuticals Inc. $35.00 09/07/2021 Non-covered Recipient Entity
Accel Research Sites - DeLand Clinical Research Unit
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828418709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/07/2021 Non-covered Recipient Entity
Accel Research Sites - DeLand Clinical Research Unit
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828418711
Principal investigator 1 PFIZER INC. $2,025.00 09/04/2021 Non-covered Recipient Entity
University Clinical ResearchDeLand LLC
A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE No dispute reported 06/30/2026 832900807
Principal investigator 1 Janssen Research & Development, LLC $3,287.00 09/03/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787819221
Principal investigator 1 Janssen Pharmaceuticals, Inc $11,379.00 09/01/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787575771
Principal investigator 1 Janssen Research & Development, LLC $2,281.00 09/01/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819093
Principal investigator 1 Moderna TX, Inc. $36,605.25 09/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342937
Principal investigator 1 PFIZER INC. $33,369.45 08/31/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832806151
Principal investigator 1 Janssen Research & Development, LLC $24,517.00 08/25/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819113
Principal investigator 1 Janssen Research & Development, LLC $2,741.00 08/25/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787819201
Principal investigator 1 Moderna TX, Inc. $67,541.85 08/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343109
Principal investigator 1 Moderna TX, Inc. $37,199.25 08/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343153
Principal investigator 1 PFIZER INC. $18,439.49 08/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 832732345
Principal investigator 1 PFIZER INC. $40,567.65 08/24/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832757446
Principal investigator 1 Eli Lilly and Company $1,500.00 08/23/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) No dispute reported 06/30/2026 819469025
Principal investigator 1 Astellas Pharma Inc $1,000.00 08/19/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function No dispute reported 06/30/2026 813552429
Principal investigator 1 Astellas Pharma Inc $1,500.00 08/19/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function No dispute reported 06/30/2026 813552435
Principal investigator 1 Astellas Pharma Inc $7,500.00 08/19/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function No dispute reported 06/30/2026 813552447
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $955.62 08/19/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 851026865
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $3,307.49 08/19/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 851026867
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,274.84 08/19/2021 Non-covered Recipient Entity
ACCEL CLINICAL
A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS No dispute reported 06/30/2026 827898499
Principal investigator 1 PFIZER INC. $12,723.83 08/14/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832726475
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,390.00 08/12/2021 Non-covered Recipient Entity
ACCEL CLINICAL
A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS No dispute reported 06/30/2026 827898491
Principal investigator 1 Janssen Research & Development, LLC $75,493.00 08/09/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819131
Principal investigator 1 PFIZER INC. $12,480.85 08/07/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832890157
Principal investigator 1 Janssen Research & Development, LLC $250.00 08/06/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787819183
Principal investigator 1 PFIZER INC. $30.00 08/05/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832785873
Principal investigator 1 PFIZER INC. $3,888.03 08/03/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832722819
Principal investigator 1 ABBVIE INC. $25.00 07/28/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects with Moderately to Severely Active Ulcerative Colitis or Crohns Disease No dispute reported 06/30/2026 792468883
Principal investigator 1 PFIZER INC. $4,775.66 07/24/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832889343
Principal investigator 1 Janssen Research & Development, LLC $16,521.00 07/23/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819148
Principal investigator 1 Janssen Research & Development, LLC $6,174.00 07/23/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787819274
Principal investigator 1 Moderna TX, Inc. $35,788.50 07/23/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343171
Principal investigator 1 PFIZER INC. $1,856.00 07/22/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832750819
Principal investigator 1 Moderna TX, Inc. $28,487.63 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342931
Principal investigator 1 Moderna TX, Inc. $26,336.14 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342949
Principal investigator 1 Moderna TX, Inc. $30,836.43 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342973
Principal investigator 1 Moderna TX, Inc. $28,875.49 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342989
Principal investigator 1 Moderna TX, Inc. $28,734.41 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343007
Principal investigator 1 Moderna TX, Inc. $32,430.11 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343025
Principal investigator 1 Moderna TX, Inc. $53,080.11 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343035
Principal investigator 1 Moderna TX, Inc. $4,921.97 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343069
Principal investigator 1 Moderna TX, Inc. $31,867.29 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343091
Principal investigator 1 Moderna TX, Inc. $13,853.57 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343115
Principal investigator 1 Moderna TX, Inc. $1,544.13 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343127
Principal investigator 1 Moderna TX, Inc. $29,209.68 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343139
Principal investigator 1 Moderna TX, Inc. $9,977.85 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343145
Principal investigator 1 Moderna TX, Inc. $11,937.71 07/21/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343177
Principal investigator 1 PFIZER INC. $750.00 07/21/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 2B RANDOMIZED DOUBLE BLIND VEHICLE CONTROLLED PARALLELGROUP DOSE RANGING STUDY TO ASSESS EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF PF06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS No dispute reported 06/30/2026 832729467
Principal investigator 1 PFIZER INC. $4,296.41 07/17/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832775061
Principal investigator 1 SEIKAGAKU CORPORATION $11,745.50 07/17/2021 Non-covered Recipient Entity
University Clinical Res-Deland, LLC (WIRE)
6603/1133 No dispute reported 06/30/2026 807679499
Principal investigator 1 Emergent BioSolutions Inc. $128,891.03 07/14/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254735
Principal investigator 1 PFIZER INC. $1,296.01 07/13/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832815327
Principal investigator 1 Moderna TX, Inc. $66,446.33 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342909
Principal investigator 1 Moderna TX, Inc. $144,108.11 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342925
Principal investigator 1 Moderna TX, Inc. $168,705.18 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342943
Principal investigator 1 Moderna TX, Inc. $53,697.26 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342959
Principal investigator 1 Moderna TX, Inc. $60,505.79 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342963
Principal investigator 1 Moderna TX, Inc. $81,286.13 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342977
Principal investigator 1 Moderna TX, Inc. $161,657.84 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806342993
Principal investigator 1 Moderna TX, Inc. $55,769.51 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343003
Principal investigator 1 Moderna TX, Inc. $38,387.25 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343019
Principal investigator 1 Moderna TX, Inc. $149,860.13 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343030
Principal investigator 1 Moderna TX, Inc. $67,300.47 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343047
Principal investigator 1 Moderna TX, Inc. $47,449.94 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343081
Principal investigator 1 Moderna TX, Inc. $164,236.95 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343099
Principal investigator 1 Moderna TX, Inc. $71,113.95 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343121
Principal investigator 1 Moderna TX, Inc. $36,784.67 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343149
Principal investigator 1 Moderna TX, Inc. $15,077.07 07/09/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343189
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,183.12 07/08/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 851025677
Principal investigator 1 PFIZER INC. $1,244.03 07/03/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832841529
Principal investigator 1 PFIZER INC. $1,991.94 06/26/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832904319
Principal investigator 1 Janssen Research & Development, LLC $40,929.00 06/25/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819045
Principal investigator 1 Janssen Research & Development, LLC $270.00 06/23/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787818931
Principal investigator 1 PFIZER INC. $2,086.44 06/22/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832795581
Principal investigator 1 Janssen Research & Development, LLC $25.00 06/18/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819023
Principal investigator 1 Moderna TX, Inc. $74,066.40 06/18/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806343075
Principal investigator 1 ABBVIE INC. $50.00 06/17/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects with Moderately to Severely Active Ulcerative Colitis or Crohns Disease No dispute reported 06/30/2026 792463353
Principal investigator 1 PFIZER INC. $1,391.86 06/12/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832771655
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 06/11/2021 Non-covered Recipient Entity
ACCEL CLINICAL
A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS No dispute reported 06/30/2026 827897265
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,220.73 06/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 851032601
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $2,143.80 06/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 851032603
Principal investigator 1 PFIZER INC. $7,958.29 06/09/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832737943
Principal investigator 1 Janssen Research & Development, LLC $200.00 06/07/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787818911
Principal investigator 1 Emergent BioSolutions Inc. $1,106.43 06/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254715
Principal investigator 1 Emergent BioSolutions Inc. $1,106.43 06/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254717
Principal investigator 1 Emergent BioSolutions Inc. $1,106.43 06/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254719
Principal investigator 1 Emergent BioSolutions Inc. $1,106.43 06/01/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254721
Principal investigator 1 PFIZER INC. $7,932.69 05/29/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832740155
Principal investigator 1 SEIKAGAKU CORPORATION $25.00 05/27/2021 Non-covered Recipient Entity
University Clinical Res-Deland, LLC (WIRE)
6603/1133 No dispute reported 06/30/2026 807679497
Principal investigator 1 Janssen Research & Development, LLC $82,025.00 05/25/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787819007
Principal investigator 1 AstraZeneca UK Limited $193.31 05/24/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH LLC
A single dose, non-randomized, open-label, parallel group study to assess the pharmacokinetics, safety and tolerability of AZD9977 in participants with renal impairment No dispute reported 06/30/2026 826474019
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 05/24/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787818893
Principal investigator 1 PFIZER INC. $15,188.97 05/22/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832796444
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $2,143.80 05/20/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 851032523
Principal investigator 1 SEIKAGAKU CORPORATION $25.00 05/20/2021 Non-covered Recipient Entity
University Clinical Res-Deland, LLC (WIRE)
6603/1133 No dispute reported 06/30/2026 807679495
Principal investigator 1 SANOFI PASTEUR INC. $4,250.00 05/19/2021 Non-covered Recipient Entity
University Clinical Research Deland,LLC
MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 No dispute reported 06/30/2026 838371121
Principal investigator 1 PFIZER INC. $19,404.30 05/15/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832763249
Principal investigator 1 PFIZER INC. $13,058.51 05/14/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 832827145
Principal investigator 1 ABBVIE INC. $25.00 05/12/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects with Moderately to Severely Active Ulcerative Colitis or Crohns Disease No dispute reported 06/30/2026 792456851
Principal investigator 1 Emergent BioSolutions Inc. $1,202.43 05/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254681
Principal investigator 1 Emergent BioSolutions Inc. $402.43 05/10/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254683
Principal investigator 1 PFIZER INC. $31,346.54 05/08/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832824539
Principal investigator 1 Emergent BioSolutions Inc. $1,102.43 05/07/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254679
Principal investigator 1 Janssen Research & Development, LLC $100.00 05/07/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787818877
Principal investigator 1 PFIZER INC. $35,908.81 05/01/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832750829
Principal investigator 1 PFIZER INC. $2,232.00 04/28/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 832819261
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $500.00 04/27/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
C3718-301 No dispute reported 06/30/2026 831592379
Principal investigator 1 Janssen Research & Development, LLC $211,743.99 04/27/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787818989
Principal investigator 1 PFIZER INC. $28,082.78 04/24/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832896849
Principal investigator 1 Janssen Research & Development, LLC $36,120.00 04/23/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787818857
Principal investigator 1 SANOFI PASTEUR INC. $2,350.00 04/23/2021 Non-covered Recipient Entity
University Clinical Research Deland,LLC
MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 No dispute reported 06/30/2026 838371113
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $6,000.00 04/22/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 851032457
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,250.00 04/22/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 851032459
Principal investigator 1 Emergent BioSolutions Inc. $6,000.00 04/21/2021 Non-covered Recipient Entity
University Clinical Research-Deland, LLC d/b/a Accel Research Sites
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents No dispute reported 06/30/2026 823607815
Principal investigator 1 PFIZER INC. $43,221.07 04/17/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832847841
Principal investigator 1 Janssen Research & Development, LLC $500.00 04/16/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787818967
Principal investigator 1 Horizon Therapeutics plc $2,031.00 04/14/2021 Non-covered Recipient Entity
AVAIL RESEARCH
A MULTICENTER EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPONSE RATES IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING KRYSTEXXA (PEGLOTICASE) (MIRROR OL ) No dispute reported 06/30/2026 811912521
Principal investigator 1 PFIZER INC. $55,969.02 04/10/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832780479
Principal investigator 1 Janssen Research & Development, LLC $500.00 04/07/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787818951
Principal investigator 1 PFIZER INC. $153,367.55 04/03/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832897179
Principal investigator 1 ABBVIE INC. $25.00 03/29/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects with Moderately to Severely Active Ulcerative Colitis or Crohns Disease No dispute reported 06/30/2026 792436029
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,657.36 03/29/2021 Non-covered Recipient Entity
University Clinical Research
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 819903457
Principal investigator 1 PFIZER INC. $132,483.77 03/27/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832835395
Principal investigator 1 Janssen Research & Development, LLC $243,009.00 03/24/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787818765
Principal investigator 1 Janssen Research & Development, LLC $45,980.00 03/24/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787818841
Principal investigator 1 PFIZER INC. $126,383.80 03/20/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832796245
Principal investigator 1 Janssen Research & Development, LLC $3,714.01 03/17/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787818746
Principal investigator 1 PFIZER INC. $133,382.70 03/16/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832769227
Principal investigator 1 PFIZER INC. $235,444.80 03/13/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832750563
Principal investigator 1 Horizon Therapeutics plc $3,000.00 03/10/2021 Non-covered Recipient Entity
AVAIL RESEARCH
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPONSE RATES IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING KRYSTEXXA (PEGLOTICASE) (MIRROR RANDOMIZED CONTROLLED TRIAL RCT ) No dispute reported 06/30/2026 811912499
Principal investigator 1 PFIZER INC. $702,170.80 03/06/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832785787
Principal investigator 1 PFIZER INC. $16,733.27 02/27/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832809686
Principal investigator 1 PFIZER INC. $1,547.31 02/24/2021 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 832796237
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $58.00 02/23/2021 Non-covered Recipient Entity
University Clinical Research
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to No dispute reported 06/30/2026 819903463
Principal investigator 1 Janssen Research & Development, LLC $91,613.00 02/23/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787818725
Principal investigator 1 Emergent BioSolutions Inc. $217.43 02/22/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254619
Principal investigator 1 Emergent BioSolutions Inc. $217.43 02/22/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254621
Principal investigator 1 Emergent BioSolutions Inc. $217.43 02/22/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254623
Principal investigator 1 Emergent BioSolutions Inc. $217.43 02/22/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254625
Principal investigator 1 Janssen Research & Development, LLC $5,670.00 02/22/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787818821
Principal investigator 1 PFIZER INC. $2,777.64 02/20/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832713297
Principal investigator 1 Janssen Research & Development, LLC $3,988.00 02/19/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787818709
Principal investigator 1 PFIZER INC. $4,773.64 02/13/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832693403
Principal investigator 1 PFIZER INC. $1,240.66 02/06/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832743773
Principal investigator 1 PFIZER INC. $2,724.80 02/05/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 2B RANDOMIZED DOUBLE BLIND VEHICLE CONTROLLED PARALLELGROUP DOSE RANGING STUDY TO ASSESS EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF PF06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS No dispute reported 06/30/2026 832905215
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 02/04/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787818799
Principal investigator 1 PFIZER INC. $6,036.57 01/30/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832723059
Principal investigator 1 SEIKAGAKU CORPORATION $2,982.00 01/28/2021 Non-covered Recipient Entity
Accel Research Sites (WIRE)
6603/1133 No dispute reported 06/30/2026 807677823
Principal investigator 1 Eli Lilly and Company $4,629.26 01/26/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819466891
Principal investigator 1 Janssen Research & Development, LLC $208,240.00 01/26/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787818693
Principal investigator 1 Janssen Research & Development, LLC $67,090.00 01/26/2021 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787818781
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254441
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254443
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254445
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254447
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254449
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254451
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254453
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254455
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254457
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254459
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254461
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254463
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254465
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254467
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254469
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254471
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254473
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254475
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254477
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254479
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254481
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254483
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254485
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254487
Principal investigator 1 Emergent BioSolutions Inc. $217.36 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254489
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254491
Principal investigator 1 Emergent BioSolutions Inc. $217.43 01/25/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
EBS.AVA.210 No dispute reported 06/30/2026 785254493
Principal investigator 1 PFIZER INC. $6,587.38 01/23/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832822939
Principal investigator 1 Eli Lilly and Company $318,936.09 01/19/2021 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819470033
Principal investigator 1 PFIZER INC. $7,160.46 01/16/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832836565
Principal investigator 1 PFIZER INC. $4,096.95 01/12/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 2B RANDOMIZED DOUBLE BLIND VEHICLE CONTROLLED PARALLELGROUP DOSE RANGING STUDY TO ASSESS EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF PF06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS No dispute reported 06/30/2026 832799615
Principal investigator 1 PFIZER INC. $6,540.13 01/08/2021 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832711871
Principal investigator 1 PFIZER INC. $156.60 01/05/2021 Non-covered Recipient Entity
Avail Clinical Research LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 832920599